Schizophrenia Market to Gain Momentum During the Forecast Period (2026-2036), with Growing Pipeline of Novel and Long-Acting Therapies | DelveInsight
The schizophrenia market is expected to showcase significant growth driven by rising disease prevalence, the expanding market for approved therapies, and the anticipated launch of new schizophrenia treatments such as Olanzapine LAI (TEV-44749/mdc-TJK; Teva Pharmaceutical/MedinCell/Royalty...
Short extract only — this publisher licenses its text. Read the full release at the source.
Cancel anytime · CA$99/month


